InnovAge Stock Forecast, Price & News

InnovAge (OTCMKTS:INNV) Frequently Asked Questions

Is InnovAge a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InnovAge in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" InnovAge stock.
View analyst ratings for InnovAge or view top-rated stocks.

How has InnovAge's stock price been impacted by Coronavirus?

InnovAge's stock was trading at $1.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INNV shares have increased by 630.9% and is now trading at $8.99.
View which stocks have been most impacted by COVID-19.

How were InnovAge's earnings last quarter?

InnovAge Holding Corp. (OTCMKTS:INNV) posted its quarterly earnings data on Tuesday, November, 9th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.01.
View InnovAge's earnings history.

What guidance has InnovAge issued on next quarter's earnings?

InnovAge issued an update on its FY 2022 earnings guidance on Tuesday, December, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $712 million-$725 million, compared to the consensus revenue estimate of $719.51 million.

What price target have analysts set for INNV?

7 Wall Street analysts have issued 1-year price targets for InnovAge's shares. Their forecasts range from $8.00 to $28.00. On average, they expect InnovAge's share price to reach $18.83 in the next twelve months. This suggests a possible upside of 109.5% from the stock's current price.
View analysts' price targets for InnovAge or view top-rated stocks among Wall Street analysts.

Who are InnovAge's key executives?

InnovAge's management team includes the following people:

• Ms. Maureen Hewitt, Pres, CEO & Director (Age 60, Pay $1.63M)
• Ms. Barbara K. Gutierrez, Chief Financial Officer (Age 58, Pay $695.77k)
• Ms. Gina DeBlassie, Chief Operations Officer of Central Region
• Mr. Edward Moore Kennedy Jr., Independent Director (Age 60, Pay $100k)
• Hon. Marilyn Barbour Tavenner R.N., Independent Director (Age 70, Pay $100k)
• Ms. Maria Lozzano, Corp. Chief Operating Officer (Age 41)
• Ms. Alice Raia, Chief Information Officer
• Ms. Vanessa D. Walton, Chief Legal Officer & Sec.
• Ms. Robin Doerr, Chief Sales & Marketing Officer (Age 57)
• Dr. Melissa Welch M.D., Chief Medical Officer (Age 60)

Who are some of InnovAge's key competitors?

Some companies that are related to InnovAge include LifeStance Health Group (LFST), Privia Health Group (PRVA), Sharecare (SHCR), Sema4 (SMFR), U.S. Physical Therapy (USPH), The Pennant Group (PNTG), Foresight Acquisition (FORE), UpHealth (UPH), Italk (TALK), CRH Medical (CRHM), Better Therapeutics (BTTX), Thimble Point Acquisition (THMA), Mountain Crest Acquisition Corp. II (MCAD), Covalon Technologies (CVALF) and Xcelerate (XCRT).
View all of INNV's competitors.

What other stocks do shareholders of InnovAge own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InnovAge investors own include EEStor Co. (ESU.V) (ESU), Antares Pharma (ATRS), Federal National Mortgage Association (FNMA), Medicines (MDCO), Frontier Communications (FTR), FedEx (FDX), Republic First Bancorp (FRBK), Aytu Biopharma (AYTU), NVIDIA (NVDA) and Pacific Premier Bancorp (PPBI).

What is InnovAge's stock symbol?

InnovAge trades on the OTCMKTS under the ticker symbol "INNV."

Who are InnovAge's major shareholders?

InnovAge's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.14%), TimesSquare Capital Management LLC (1.14%), Maverick Capital Ltd. (0.85%), William Blair Investment Management LLC (0.84%), Camber Capital Management LP (0.74%) and Bank of New York Mellon Corp (0.68%). Company insiders that own InnovAge stock include Edward Moore Jr Kennedy and Maureen Hewitt.
View institutional ownership trends for InnovAge.

Which major investors are selling InnovAge stock?

INNV stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Rock Springs Capital Management LP, Capital Research Global Investors, Camber Capital Management LP, Geode Capital Management LLC, TimesSquare Capital Management LLC, California State Teachers Retirement System, and Alliancebernstein L.P..
View insider buying and selling activity for InnovAge or view top insider-selling stocks.

Which major investors are buying InnovAge stock?

INNV stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Morgan Stanley, Maverick Capital Ltd., Millennium Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Tudor Investment Corp Et Al, and Cambiar Investors LLC. Company insiders that have bought InnovAge stock in the last two years include Edward Moore Jr Kennedy, and Maureen Hewitt.
View insider buying and selling activity for InnovAge or or view top insider-buying stocks.

How do I buy shares of InnovAge?

Shares of INNV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InnovAge's stock price today?

One share of INNV stock can currently be purchased for approximately $8.99.

How much money does InnovAge make?

InnovAge has a market capitalization of $1.22 billion and generates $637.80 million in revenue each year.

How many employees does InnovAge have?

InnovAge employs 1,800 workers across the globe.

What is InnovAge's official website?

The official website for InnovAge is www.innovuspharma.com.

Where are InnovAge's headquarters?

InnovAge is headquartered at 8845 Rehco Road, San Diego CA, 92121.

How can I contact InnovAge?

InnovAge's mailing address is 8845 Rehco Road, San Diego CA, 92121. The company can be reached via phone at 844-803-8745 or via email at [email protected].